enGene Announces Name Change to enGene Therapeutics Inc.
Name change reflects transition towards potential commercial organization in 2027 Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026
enGene Appoints Ryan Daws as Chief Financial Officer
/CNW/ - enGene Holdings Inc. ("enGene,") (NASDAQ: ENGN) (NASDAQ: ENGNW), a clinical-stage genetic medicines company whose lead program is in a pivotal study...